
Hoth Therapeutics Inc (NASDAQ:HOTH) shares are trading higher by 125.5% at $1.38 after the company said its mRNA frame-shifting therapeutic proved effective against aggressive cancer cells.
Hoth says treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours. According to Hoth, HT-KIT also inhibits tumor growth and systemic organ infiltration using both an allograft mastocytosis model and a humanized xenograft MC tumor model.